"The trial of drug Anavex 2-73 has already had some success with patients’ personalities restored, skills they had not been able to use for years returned and many of the memories that had been locked away, now remembered.
On average the group remained stable and did not decline, which was expected with a group of 32 Alzheimer’s patients.
Anavex 2-73 is a drug designed to not only relieve the symptoms of Alzheimer’s Disease, but also slow the progression. It works by blocking proteins in the brain, which prevents the oxidative stress and cell death seen in the brains of people Alzheimer’s Disease.
The Phase 2 trial has assessed 32 people with mild to moderate Alzheimer’s Disease, with some very positive results. One of the test participants can now play piano again, while another – award-winning artist Valerie Lynch, says the drug has allowed her to be able to paint again. Others experienced an improvement in memory, mood and humour.
The goal of this particular trial was to determine the maximum tolerated dose of the drug, while also assessing participant’s resulting cognitive skill, blood results, and brain scans
News 
Market Data 
Discover 
